Cargando…
Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report
Anaemia is a common occurrence in patients with cancer, and currently can be treated in several ways. Novel erythropoiesis stimulating protein (NESP, darbepoetin alfa) was created using site-directed mutagenesis to have 8 more sialic acid side chains than recombinant human erythropoietin (rHuEPO). T...
Autores principales: | Heatherington, A C, Schuller, J, Mercer, A J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363902/ https://www.ncbi.nlm.nih.gov/pubmed/11308269 http://dx.doi.org/10.1054/bjoc.2001.1747 |
Ejemplares similares
-
Development and characterization of novel erythropoiesis stimulating protein (NESP)
por: Egrie, J C, et al.
Publicado: (2001) -
Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer
por: Smith, R E, et al.
Publicado: (2001) -
A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy
por: Glaspy, J, et al.
Publicado: (2001) -
Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP(®)) Biosimilar, to Those of NESP(®) After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
por: Jeon, Inseung, et al.
Publicado: (2021) -
NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumours of the pancreas and adrenal medulla but not in ileal carcinoids
por: Jakobsen, A-M, et al.
Publicado: (2003)